L3VLUP
ProSign in

ALNY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALNYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALNY
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterALNYVRTX
Q3 202013 holders, $7.6bn31 holders, $21.9bn
Q4 202013 holders, $6.5bn30 holders, $18.4bn
Q1 202114 holders, $7.2bn31 holders, $15.4bn
Q2 202113 holders, $8.8bn30 holders, $12.7bn
Q3 202114 holders, $9.7bn35 holders, $10.1bn
Q4 202112 holders, $8.8bn28 holders, $12.4bn
Q1 202212 holders, $8.9bn23 holders, $16.1bn
Q2 202213 holders, $8.1bn25 holders, $18.1bn
Q3 202217 holders, $10.8bn22 holders, $18.4bn
Q4 202216 holders, $13.7bn28 holders, $18.4bn
Q1 202319 holders, $11.5bn26 holders, $21.4bn
Q2 202316 holders, $10.6bn27 holders, $24.7bn
Q3 202317 holders, $9.7bn33 holders, $24.3bn
Q4 202315 holders, $10.0bn32 holders, $28.6bn
Q1 202415 holders, $7.3bn31 holders, $29.8bn
Q2 202419 holders, $12.5bn29 holders, $33.4bn
Q3 202418 holders, $15.1bn27 holders, $33.5bn
Q4 202415 holders, $12.8bn26 holders, $28.5bn
Q1 202518 holders, $14.9bn21 holders, $35.4bn
Q2 202522 holders, $18.3bn21 holders, $32.3bn
Q3 202533 holders, $26.6bn22 holders, $25.9bn
Q4 202524 holders, $23.4bn26 holders, $31.8bn
Q1 202622 holders, $17.9bn25 holders, $31.8bn
Q2 202621 holders, $15.9bn26 holders, $34.6bn
ALNY

Alnylam Pharmaceuticals Inc

Holders
15
Reported value
$7.3bn
Buyers
10
Sellers
6

Breadth +4 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALNY (6)

Baillie Gifford & Co, Dodge & Cox, Farallon Capital Management LLC, Hudson Bay Capital Management LP, Point72 Asset Management LP, Squarepoint Ops LLC

Only VRTX (22)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Tudor Investment Corp, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →